Periodic Reporting for period 1 - SAGAPROPLUS (A Unique Herbal Product for the Symptomatic Treatment of Over Active Bladder) Periodo di rendicontazione: 2017-08-01 al 2017-11-30 Sintesi del contesto e degli obiettivi generali del progetto Over active bladder (OAB) is an age-related syndrome, more frequent in adults +65. It is extremely common, affecting ~500 million people and expected to keep rising due to aging of developed societies. OAB represents a human and economical burden for which no good solutions are available. OAB treatment has two lines of intervention: i) changes in lifestyle (diet, Kegel exercises) that are only partially effective and dependent on patients’ commitment, and ii) pharmacological treatment (anticholinergic drugs that inhibit contraction of bladder muscles), only partially effective and associated with multiple side effects, resulting in extremely high drop-out rates. SagaMedica has identified the need for better treatments for OAB and has developed SagaPro+, a natural solution for dealing with OAB symptoms. SagaPro+ is made from leaves of plant Angelica Archangelica, and offers unique properties for OAB management: i) efficiency: SagaPro+ has been validated in OAB patients who reported an improvement of their symptoms, ii) safety: no side effects have been observed, iii) natural origin: SagaPro+ is 100% natural and consists only of Angelica extracts, and iv) sustainability: its harvesting and manufacturing processes have been kept local, sustainable and eco-friendly. Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti We have performed a study to confirm viability of SAGAPRO+: i) technically we designed a large-scale clinical trial and defined the requirements for industrialization, ii) commercially we investigated the regulatory pathway for SagaPro+, as well as carried out a detailed study of OAB market, and iii) financially, we updated our business plan and confirmed project’s profitability. Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora) Economic impact: SagaPro+’s affordable price will alleviate both direct and indirect costs of OAB management to the healthcare system. Societal impact: a natural solution like SagaPro+ will alleviate the symptoms without side effects improving the quality of life of affected patients allowing them to have a normal everyday life.